Caring Ambassadors Hepatitis C Program Newsletter
www.HepCChallenge.org
July 2010
Clinical Trials, Cohort Studies, Pilot Studies
Two week
induction of interferon-beta followed by pegylated interferon alpha-2b and
ribavirin for chronic infection with hepatitis C. Matsui K, Iwabuchi S, Shimizu H, et al. Hepatol Res. 2010 Jun 8. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20557368
Identifying
hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated
course of peginterferon alfa-2a (40KD) plus ribavirin. Diago M, Shiffman ML, Bronowicki JP, et al. Hepatology. 2010
Jun;51(6):1897-903.
http://www.ncbi.nlm.nih.gov/pubmed/20196118
Efficacy and
safety of combination therapy of natural human interferon beta and ribavirin in
chronic hepatitis C patients with genotype 1b and high virus load. Arase Y, Suzuki F, Akuta N, et al. Intern Med. 2010;49(11):957-63. Epub
2010 Jun 1.
http://www.ncbi.nlm.nih.gov/pubmed/20519809
Availability
of body art facilities and body art piercing do not predict hepatitis C acquisition
among injection drug users in Montreal, Canada: Results from a cohort study.
Bruneau J, Daniel M, Kestens Y, Abrahamowicz M, Zang G. Int J Drug
Policy. 2010 Jun 10. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20541926
Metabolic
disorders associated with chronic hepatitis C: impact of genotype and
ethnicity.
Sersté T, Nkuize M, Moucari R, et al. Liver Int. 2010 Jun 9. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/20536721
Influence of
body mass index on outcome of pediatric chronic hepatitis c virus infection. Delgado-Borrego A, Healey D, Negre B, et al. J Pediatr Gastroenterol
Nutr. 2010 Jun 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20531022
Hepatitis C
virus infection is significantly associated with malignant lymphoma in Taiwan,
particularly with nodal and splenic marginal zone lymphomas. Chuang SS, Liao YL, Chang ST, et al. J Clin Pathol. 2010 Jun 7. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20530156
Nail changes
in patients with liver disease. Salem A,
Gamil H, Hamed M, Galal S. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):649-54.
Epub 2009 Nov 2.
http://www.ncbi.nlm.nih.gov/pubmed/19888943
The H63D
genetic variant of the HFE gene is independently associated with the
virological response to interferon and ribavirin therapy in chronic hepatitis
C. Carneiro MV, Souza FF, Teixeira AC, et al. Eur J
Gastroenterol Hepatol. 2010 Jun 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20555268
Basic and Applied Science, Pre-Clinical Studies
Variants in
the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease
the need for ribavirin dose reduction. Thompson AJ,
Fellay J, Patel K, et al. Gastroenterology. 2010 Jun 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20547162
Positive
selection of core 70Q variant genotype 1b hepatitis C virus strains induced by
pegylated interferon and ribavirin. Kurbanov F,
Tanaka Y, Matsuura K, et al. J Infect Dis. 2010 Jun 1;201(11):1663-71.
http://www.ncbi.nlm.nih.gov/pubmed/20420509
Wild-type hepatitis C virus core inhibits the
initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Zhu W, Chang
Y, Wu C, Han Q, Pei R, Lu M, Chen X. Clin Vaccine Immunol. 2010 Jun 2. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20519445
PSI-7851, a Pronucleotide of
{beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate: A potent and
pan-genotype inhibitor of hepatitis c virus replication.
Lam AM,
Murakami E, Espiritu C, et al. Antimicrob Agents Chemother. 2010 Jun 1. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20516278
Phosphoramidate ProTides of
2'-C-Methylguanosine as highly potent inhibitors of hepatitis c virus. Study of
their in vitro and in vivo properties. McGuigan C, Gilles A, Madela K, et al.
J Med Chem. 2010 Jun 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20527890
Prediction of prognostic biomarkers for
Interferon-based therapy to Hepatitis C Virus patients : a metaanalysis of the
NS5A protein in subtypes 1a, 1b, and 3a. Elhefnawi MM, Zada S, El-Azab IA. Virol
J. 2010 Jun 15;7(1):130. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20550652
Association of NKG2A with treatment for
chronic hepatitis C virus infection. Harrison RJ, Ettorre A, Little AM,
Khakoo SI. Clin Exp Immunol. 2010 Jun 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20550548
Intracytoplasmic stable expression of IgG1
antibody targeting NS3 helicase inhibits replication of highly efficient
hepatitis C Virus 2a clone. Chandra PK, Hazari S, Poat B, et al.
http://www.ncbi.nlm.nih.gov/pubmed/20529250
Interferon-lambda genotype and low serum
low-density lipoprotein cholesterol levels in patients with chronic hepatitis C
infection. Li
JH, Lao XQ, Tillmann HL, et al. Hepatology. 2010 Jun;51(6):1904-11.
http://www.ncbi.nlm.nih.gov/pubmed/20235331
Hepatocyte growth factor and chronic
hepatitis C. Marín-Serrano E, Rodríguez-Ramos C, Díaz-García F, et al.
Rev Esp Enferm Dig. 2010 Jun;102(6):365-71.
http://www.ncbi.nlm.nih.gov/pubmed/20575596
HIV/HCV Coinfection
The impact
of HIV/HCV co-infection on health care utilization and disability: Results of
the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.
Linas BP, Wang B, Smurzynski M, et al. J Viral Hepat. 2010 Jun 9. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20546501
Insulin resistance
impairs response to interferon plus ribavirin in patients coinfected with HIV
and hepatitis C virus. Ryan P, Resino S,
Miralles P, Cosín J, et al. J Acquir Immune Defic Syndr. 2010 Jun 23. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20577091
Clearance of
hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates
eradication from peripheral blood mononuclear cells. Page EE, Cox A, Atkins M, Nelson MR. AIDS. 2010 Jun 1;24(9):1267-71.
http://www.ncbi.nlm.nih.gov/pubmed/20386424
Impact of
hepatitis C virus coinfection on HAART in HIV-infected individuals: multi-centric
observation cohort. Fuping G, Wei L,
Yang H, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):137-42.
http://www.ncbi.nlm.nih.gov/pubmed/20431395
Safety,
tolerability, and mechanisms of antiretroviral activity of pegylated interferon
Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. Asmuth DM, Murphy RL, Rosenkranz SL, et al. J Infect Dis. 2010 Jun
1;201(11):1686-96.
http://www.ncbi.nlm.nih.gov/pubmed/20420510
The effects
of opiate use and hepatitis C virus infection on risk of diabetes mellitus in
the Women's Interagency HIV Study. Howard AA,
Hoover DR, Anastos K, et al. J Acquir Immune Defic Syndr. 2010 Jun;54(2):152-9.
http://www.ncbi.nlm.nih.gov/pubmed/20190642
Hepatitis C transmission,
prevention, and treatment knowledge among patients with HIV. Proeschold-Bell RJ, Blouin R, Reif S, et al. South Med J. 2010 Jun 4.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20531062
Hepatitis B
and hepatitis C seroprevalence in children receiving antiretroviral therapy for
human immunodeficiency virus-1 infection in China, 2005-2009. Zhou S, Zhao Y, He Y, et al. J Acquir Immune Defic Syndr. 2010
Jun;54(2):191-6.
http://www.ncbi.nlm.nih.gov/pubmed/20032784
Interleukin-27,
an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. Frank AC, Zhang X, Katsounas A, et al. J Interferon Cytokine Res. 2010
Jun;30(6):427-31. Bharucha JP,
http://www.ncbi.nlm.nih.gov/pubmed/20235668
Need to improve routine HIV testing of U.S.
Veterans in care: Results of an internet survey.
Valdiserri
RO, Nazi K, McInnes DK, Ross D, Kinsinger L. J Community Health. 2010
Jun;35(3):215-9.
http://www.ncbi.nlm.nih.gov/pubmed/20146092
Complementary and Alternative Medicine
Acupuncture
for depression and myalgia in patients with hepatitis: an observational study.
Tufan ZK, Arslan H, Yildiz F, et al. Acupunct Med. 2010 Jun 7. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20530097
Antioxidant
and immunomodulatory effects of Viusid in patients with chronic hepatitis C.
Gomez EV, Perez YM, Sanchez HV, et al. World J Gastroenterol. 2010 Jun
7;16(21):2638-47.
http://www.ncbi.nlm.nih.gov/pubmed/20518086
Colchicine
reduces procollagen III and increases pseudocholinesterase in chronic liver
disease. Muntoni S, Rojkind M, Muntoni S. World J
Gastroenterol. 2010 Jun 21;16(23):2889-94.
http://www.ncbi.nlm.nih.gov/pubmed/20556834
Epidemiology, Diagnostics, and Miscellaneous Works
A novel duplex real-time reverse
transcriptase-polymerase chain reaction assay for the detection of hepatitis C
viral RNA with armored RNA as internal control. Meng S, Li
J. Virol J. 2010 Jun 7;7(1):117. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20529244
Soluble inflammatory markers as predictors of
liver histological changes in patients with chronic hepatitis C virus
infection. Moura
AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO. Eur J Clin Microbiol Infect Dis.
2010 Jun 18. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20559676
Non-invasive index for predicting significant
liver fibrosis: comparison of diagnostic performances in patients with chronic
hepatitis B and C. Cheong JY, Um SH, Seo YS, et al. Dig Dis Sci.
2010 Jun 29. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20585981
Viral response to specifically targeted
antiviral therapy for hepatitis C and the implications for treatment success. Cooper C. Can
J Gastroenterol. 2010 Jun;24(6):385-90.
http://www.ncbi.nlm.nih.gov/pubmed/20559582
Pharmacy participation in non-prescription
syringe sales in Los Angeles and San Francisco Counties, 2007. Cooper EN,
Dodson C, Stopka TJ, et al. J Urban
Health. 2010 Jun 12. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20549568
Current risks of occupational blood-borne
viral infection. Mohebati A, Davis JM, Fry DE. Surg Infect (Larchmt). 2010
Jun;11(3):325-31.
http://www.ncbi.nlm.nih.gov/pubmed/20528133
Chronic hepatitis C in the state prison
system: insights into the problems and possible solutions. Imperial JC.
Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):355-64.
http://www.ncbi.nlm.nih.gov/pubmed/20528122
Timing of hepatitis C antiviral therapy in
patients with advanced liver disease: a decision analysis model. Saab S, Hunt
DR, Stone MA, McClune A, Tong MJ. Liver Transpl. 2010 Jun;16(6):748-59.
http://www.ncbi.nlm.nih.gov/pubmed/20517909
Development of a low-cost real-time reverse
transcriptase-polymerase chain reaction technique for the detection and
quantification of hepatitis C viral load. Shahzamani K, Merat S, Rezvan H, et
al. Clin Chem Lab Med. 2010 Jun;48(6):777-84.
http://www.ncbi.nlm.nih.gov/pubmed/20218905
How stable is the hepatitis C virus (HCV)?
Environmental stability of HCV and its susceptibility to chemical biocides. Ciesek S,
Friesland M, Steinmann J, et al. J Infect Dis. 2010 Jun 15;201(12):1859-66.
http://www.ncbi.nlm.nih.gov/pubmed/20441517
The role of physician and nurse attitudes in
the health care of injecting drug users.
Brener L,
Von Hippel W, Kippax S, Preacher KJ. Subst Use Misuse. 2010
Jun;45(7-8):1007-18.
http://www.ncbi.nlm.nih.gov/pubmed/20441447
Patient preferences and assessment of likely
adherence to hepatitis C virus treatment.
Brett Hauber
A, Mohamed AF, Beam C, Medjedovic J, Mauskopf J. J Viral Hepat. 2010 Jun 22.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/20579276
Hepatitis C virus infections from unsafe
injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Fischer GE,
Schaefer MK, Labus BJ, et al. Clin Infect Dis. 2010 Jun 24. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20575663
Epidemiology, Surveillance, and Prevention of
Hepatitis C Virus Infections in Hemo-dialysis Patients. Patel PR,
Thompson ND, Kallen AJ, Arduino MJ. Am J Kidney Dis. 2010 Jun 4. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/20570422
The Ribavirin Pregnancy Registry: Findings
after 5 years of enrollment, 2003-2009.
Roberts SS,
Miller RK, Jones JK, et al. Birth Defects Res A Clin Mol Teratol. 2010 Jun 17.
[Epub ahead of print]